Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 33 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

6%

2 trials in Phase 3/4

Results Transparency

21%

7 of 33 completed trials have results

Key Signals

7 with results

Enrollment Performance

Analytics

Phase 1
25(75.8%)
Phase 2
6(18.2%)
Phase 3
2(6.1%)
33Total
Phase 1(25)
Phase 2(6)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (33)

Showing 20 of 33 trials
NCT04784533Phase 2Completed

A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Role: lead

NCT04158687Phase 2Completed

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia

Role: lead

NCT04797650Phase 3Completed

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

Role: lead

NCT04518995Phase 3Completed

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)

Role: lead

NCT03941548Phase 2Completed

Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata

Role: lead

NCT03811912Phase 2Completed

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

Role: lead

NCT05468749Phase 1Completed

Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543

Role: lead

NCT05467722Phase 1Completed

Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

Role: lead

NCT05478772Phase 1Completed

Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

Role: lead

NCT05467709Phase 1Completed

Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects

Role: lead

NCT05467696Phase 1Completed

Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers

Role: lead

NCT03137381Phase 2Completed

Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

Role: lead

NCT05192369Phase 1Completed

A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers

Role: lead

NCT01487109Phase 2Completed

A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

Role: lead

NCT04843540Phase 1Completed

Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects

Role: lead

NCT04743414Phase 1Completed

Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects

Role: lead

NCT04309643Phase 1Completed

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

Role: lead

NCT04092712Phase 1Completed

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

Role: lead

NCT03880253Phase 1Completed

Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers

Role: lead

NCT03880136Phase 1Completed

Food Effect Study of CTP-543 in Healthy Volunteers

Role: lead